AVITA Medical to Present at the Piper Sandler 36th Annual Healthcare Conference
AVITA Medical to Present at the Piper Sandler 36th Annual Healthcare Conference
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time.
加利福尼亚州瓦伦西亚，2024年11月25日（GLOBE NEWSWIRE）——专注于伤口护理管理和皮肤修复的一流设备的商业阶段再生医学公司AVITA Medical, Inc.（纳斯达克股票代码：RCEL，澳大利亚证券交易所股票代码：AVH）今天宣布，首席执行官吉姆·科贝特将于2024年12月3日星期二出席派珀·桑德勒第36届年度医疗保健大会，美国东部时间上午 11:30。
A live webcast of the fireside chat will be accessible under the Events & Presentations section of the Company's website at . A replay of the webcast will be available following the conclusion of the event.
可以在公司网站的 “活动和演讲” 部分下观看炉边谈话的网络直播，网址为。活动结束后，将重播网络直播。
About AVITA Medical, Inc.
AVITA Medical is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, and Cohealyx, an AVITA Medical-branded collagen-based dermal matrix.
关于 AVITA Medical, Inc.
AVITA Medical是一家处于商业阶段的再生医学公司，通过创新设备改变了伤口护理管理和皮肤修复的护理标准。我们平台的最前沿是RECELL系统，该系统已获得美国食品药品监督管理局的批准，用于治疗热烧伤口和全层皮肤缺陷，以及对稳定的脱色白癜风病变进行色素沉着。RECELL 利用患者自身皮肤的再生特性来创建喷雾式皮肤细胞，为护理点提供变革性解决方案。这项突破性技术是新治疗模式的催化剂，可以改善临床结果。在美国，AVITA Medical还拥有营销、销售和分销生物合成伤口基质Permeaderm和AVITA Medical品牌基于胶原蛋白的皮肤基质Cohealyx的独家权利。
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
在国际市场上，RECELL 系统经批准可在多种应用中促进皮肤愈合，包括烧伤、全层皮肤缺陷和白癜风。RECELL 系统已在澳大利亚注册 TGA，已在欧洲获得 CE 标志批准，并在日本获得 PMDA 批准。
To learn more, visit .
要了解更多信息，请访问。
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
已获AVITA Medical, Inc.首席财务官授权发布
CONTACT: Investor & Media Contact:
Jessica Ekeberg
Phone +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com
联系人：投资者和媒体联系人：
杰西卡·埃克伯格
电话 +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com
